Aktis Oncology, Inc.
AKTS
$25.00
$0.281.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 4.87% | 72.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.87% | 72.57% | |||
| Cost of Revenue | 26.17% | 21.48% | |||
| Gross Profit | -30.26% | -14.95% | |||
| SG&A Expenses | 18.76% | 114.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.49% | 34.75% | |||
| Operating Income | -27.27% | -30.68% | |||
| Income Before Tax | -31.75% | -21.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -31.75% | -21.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -31.75% | -21.05% | |||
| EBIT | -27.27% | -30.68% | |||
| EBITDA | -27.05% | -32.22% | |||
| EPS Basic | -15.87% | 97.93% | |||
| Normalized Basic EPS | -15.88% | 97.93% | |||
| EPS Diluted | -15.87% | 97.93% | |||
| Normalized Diluted EPS | -15.88% | 97.93% | |||
| Average Basic Shares Outstanding | 13.72% | 5,750.58% | |||
| Average Diluted Shares Outstanding | 13.72% | 5,750.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||